Brokers Offer Predictions for MSLE FY2030 Earnings

Satellos Bioscience Inc. (NASDAQ:MSLE) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for Satellos Bioscience in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst A. He forecasts that the company will post earnings of $0.34 per share for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock.

Satellos Bioscience (NASDAQ:MSLE) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.11).

Several other research firms have also issued reports on MSLE. Zacks Research upgraded shares of Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. Cantor Fitzgerald began coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They set an “overweight” rating for the company. Weiss Ratings began coverage on Satellos Bioscience in a research note on Wednesday, February 11th. They set a “sell (d-)” rating for the company. Finally, Wall Street Zen cut Satellos Bioscience to a “strong sell” rating in a report on Saturday, March 14th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $11.00.

Satellos Bioscience Stock Performance

NASDAQ MSLE opened at $5.63 on Tuesday. Satellos Bioscience has a 12 month low of $4.53 and a 12 month high of $13.39. The company has a market capitalization of $87.04 million, a P/E ratio of -3.63 and a beta of 1.10.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.